HGFR/c-Met Antibody (MMAE)

• Catalog Number: orb1805476
• Category: Antibodies
• Description: Anti-HGFR / c-Met Reference Antibodydy and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.
• Target: HGFR / c-Met
• Clonality: Recombinant
• Conjugation: MMAE
• Reactivity: Human
• Concentration: Batch dependent
• Buffer/Preservatives: 100 mM Proline/Acetic acid 20mM Arginine pH 5.0
• Purity: >95%
• Purification: Protein A
• UniProt ID: P08581
• MW: 151.37 kDa
• Tested applications: ELISA, FA, FACS, In vivo
• Antibody Type: Recombinant Antibody
• Expression System: CHO
• Endotoxins: <0.001 EU/ug
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Note: For research use only

Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin)is more than 95% ;determined by SEC-HPLC.

Immobilized human cMet His at 2 μg/mL can bind Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin);EC50=0.105μg/mL.